Stories

A decade ago, medicine development looked very different. Today, some of the most exciting science is coming from small, focused teams moving at speed – teams working under real operational constraints, with little room for anything that slows them down. 

For a company like Ipsen, environmental impact doesn’t stop at the boundaries of its operations. In fact, that’s only a small part of the picture.

In biopharmaceutical research, not all challenges are equal. Some of the most meaningful opportunities lie in areas defined by complex biology, limited evidence, and patients who have waited far too long for effective treatment options.  

In today’s rapidly evolving treatment landscape the approval of a medicine is no longer the finish line; it’s just the beginning. Real world evidence (RWE), post-hoc analyses and structured Phase IV studies all offer new opportunities for scientific learning. At Ipsen, we’re committed to pursuing the unanswered questions, generating robust evidence that goes beyond medicine development, which provides broader long-term evidence-based perspectives for the communities we serve. 

A diagnosis is supposed to be the end of the uncertainty. For some families, it is also the moment they realize there is nothing more medicine can offer. Loubna Ouriaghli, Head of Government Affairs & Policy at Ipsen, witnessed that moment with her own mother who was diagnosed with a rare disease.  She saw the symptoms appear one by one, the years it took to finally have an answer and the silence that followed when that answer came with no treatment.